Pacira's EXPAREL patent invalidated by New Jersey court; company plans appeal

Pacira BioSciences, Inc.

U.S. District Court for D.N.J. ruled Pacira's U.S. Patent No. 11,033,495 for EXPAREL is invalid.
Company intends to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.
Three separate infringement suits against eVenus remain ongoing; additional patents pending.
CEO Frank D. Lee stated belief in patent strength and that EXPAREL franchise is well protected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.